Patents by Inventor Peter End

Peter End has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220016103
    Abstract: Described herein are methods of treating paroxysmal nocturnal hemoglobinuria (PNH) with the Factor B inhibitor LNP023 or a pharmaceutically acceptable salt thereof, e.g. LNP023 hydrochloride.
    Type: Application
    Filed: July 15, 2021
    Publication date: January 20, 2022
    Inventors: Irina BALTCHEVA, Peter END, Julie Marie-Pomme Gabrielle MILOJEVIC
  • Publication number: 20140323494
    Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
    Type: Application
    Filed: July 14, 2014
    Publication date: October 30, 2014
    Applicant: Novartis AG
    Inventors: Klaus O. Börnsen, Peter End, Gerhard Gross, Ulrike Pfaar, Paul W. Manley, Jürg Zimmermann
  • Publication number: 20130197016
    Abstract: The use of vascular endothelial growth factor receptor 2 inhibitors or a pharmaceutically acceptable salt thereof for the treatment of ocular vascular disease is provided. Dosing regimes, including once weekly administration, of certain VEGF-R2 inhibitors are provided which deliver therapeutically effective concentrations of the VEGF-R2 compounds in ocular tissues for at least one week for the treatment of ocular vascular disease.
    Type: Application
    Filed: October 25, 2011
    Publication date: August 1, 2013
    Inventors: Mitchell Brigell, Peter End, Vinayak Hosagrahara, Bruce D. Jaffee, Erik Meredith, Ronald Keith Newton, Stephen Poor, Yubin Qiu
  • Publication number: 20110294820
    Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
    Type: Application
    Filed: July 5, 2011
    Publication date: December 1, 2011
    Inventors: Klaus Olaf Börnsen, Peter End, Gerhard Gross, Ulrike Pfaar, Paul William Manley, Jürg Zimmerman
  • Publication number: 20100222362
    Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
    Type: Application
    Filed: May 17, 2010
    Publication date: September 2, 2010
    Inventors: Klaus Olaf Börnsen, Peter End, Gerhard Gross, Ulrike Pfaar, Paul William Manley, Jürg Zimmermann
  • Publication number: 20090239879
    Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
    Type: Application
    Filed: June 4, 2009
    Publication date: September 24, 2009
    Inventors: Klaus Olaf BORNSEN, Peter END, Gerhard GROSS, Ulrike PFAAR, Paul William MANLEY, Jurg ZIMMERMANN
  • Patent number: 7557105
    Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
    Type: Grant
    Filed: January 22, 2003
    Date of Patent: July 7, 2009
    Assignee: Novartis AG
    Inventors: Klaus Olaf Börnsen, Peter End, Gerhard Gross, Ulrike Pfaar, Paul William Manley, Jürg Zimmermann
  • Publication number: 20050209452
    Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.
    Type: Application
    Filed: January 22, 2003
    Publication date: September 22, 2005
    Inventors: Klaus Bornsen, Peter End, Gerhard Gross, Ulrike Pfaar, Paul Manley, Jurg Zimmermann
  • Patent number: 5741689
    Abstract: The invention provides for a method to inhibit the binding between the p85 and p110 subunits of said PI3-kinase and thus a method to modulate PI3-kinase activity and modulate the response of cells to external stimuli. In particular, disabling, by conventional means, residues located in the inter-SH2 domain of said p85 subunit, specifically a region containing amino acid residue 478 to amino acid residue 513 of p85.alpha. subunit, or amino acid residue 445 to amino acid residue 485 of p85.beta. subunit of said PI3-kinase. Interference with these binding regions will affect binding between the subunits and results in inhibiting PI3-kinase activity. This invention further relates to a methods to modulate the serine kinase activity of the PI3-kinase which can be achieved by disabling the DRHNSN sequence of the p110 subunit and can also be used to effect changes in overall PI3-kinase activity. This invention is further related to an (ant)agonist which affects serine kinase activity of PI3-kinase.
    Type: Grant
    Filed: January 21, 1994
    Date of Patent: April 21, 1998
    Assignee: Ludwig Institute for Cancer Research
    Inventors: Ritu Bala Dhand, Michael Derek Waterfield, Ian Donald Hiles, Ivan Tarasovich Gout, Masato Kasuga, Kazuyoshi Yonezawa, Peter End, Michael Fry, George Panayotou
  • Patent number: 5738825
    Abstract: A detection cell which is used as a component of an optical biosensor comprises a transparent base plate and a sample plate on the base plate. The sample plate has a matrix of wells extending through it to each to receive a sample. The base plate includes a waveguiding film and a diffraction grating means to in couple an incident light field into the waveguiding film beneath a well to generate a diffracted light field to enable detection of a change in the effective refractive index of the waveguiding film.
    Type: Grant
    Filed: May 12, 1997
    Date of Patent: April 14, 1998
    Assignees: Balzers Aktiengesellschaft, Artificial Sensing Instruments ASI AG
    Inventors: Helmut Rudigier, Roland Pfefferkorn, Kurt Tiefenthaler, Veronique Briquet, Alois Zetting, Peter Marbach, Francois Legay, Peter End